Electra Therapeutics, Inc. (ETRA) IPO filing analysis

One-minute decisionBASIC RESEARCHSource completeness · 78%

IPO research

As of the September 17, 2026 prospectus and September 18, 2026 filing, Electra Therapeutics is offering a priced IPO of common stock to fund late-stage clinical development, but remains pre-revenue, loss-making, dependent on clinical and regulatory execution, and subject to substantial financing and manufacturing risks. The filing does not establish that trading or closing has occurred.

Electra Therapeutics’ filed 424B4 prospectus describes a $15.00-per-share IPO of 23,333,334 common shares, with expected delivery on or about September 21, 2026, subject to completion conditions.

Where does the money go?Awaiting verification424B4 · 2026-09-18

Ownership and votingAwaiting verified holder data— economic · — voting

Next disclosed checkpointExpected share delivery is on or about September 21, 2026; this is a prospectus expectation, not confirmation of closing or trading. The underwriter option may be exercised within 30 days of the prospectus date.424B4 · 2026-09-18

Capital destination

Awaiting verification

424B4 · 2026-09-18

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · 424B4 ↗

Next checkExpected share delivery is on or about September 21, 2026; this is a prospectus expectation, not confirmation of closing or trading. The underwriter option may be exercised within 30 days of the prospectus date.

Latest filing2026-09-21

Capital destination

Awaiting verification

424B4 · 2026-09-18

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · 424B4 ↗

BOOKRUNNERS / LEAD UNDERWRITERSBookrunners / lead underwriters

NOT YET DISCLOSED

Names not yet published

Fully diluted valuation bridge

Status	Reference
Awaiting verification	Source ↗

Basic-price scenario

A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.

Check the source · 424B4 ↗

Holder data awaits verification

After the offering, Electra officers, directors, pre-offering 5% holders and affiliates are expected to hold approximately 33.1%, assuming no group purchases. Principal-stockholder data are based on August 1, 2026 and include conversion shares; the excerpts do not provide a complete voting-rights reconciliation. · 2026-09-18

After the offering, Electra officers, directors, pre-offering 5% holders and affiliates are expected to hold approximately 33.1%, assuming no group purchases. Principal-stockholder data are based on August 1, 2026 and include conversion shares; the excerpts do not provide a complete voting-rights reconciliation.

One disclosed holder; not a complete ownership distribution.Check the source · 424B4 ↗

Conditional lock-up timeline

Status	Reference
Awaiting verification	Source ↗

Financial quality and runway

Status	Reference
Awaiting verification	Source ↗

Latest filing update

Loading saved filing update…

SEC filing history

Loading filing history…

Risk 1

Positive early clinical results may not predict registrational or later-stage outcomes; enrollment and regulatory approval remain uncertain.

Potential impact: Awaiting verification
Monitor: Expected share delivery is on or about September 21, 2026; this is a prospectus expectation, not confirmation of closing or trading. The underwriter option may be exercised within 30 days of the prospectus date.
Evidence: Summary of Risk Factors ↗

SEC EDGAR

424B4

2026-09-21

Open SEC filing ↗